Rene Goedkoop - Medigene Acting Officer

MDGEFDelisted Stock  USD 2.59  0.00  0.00%   

Insider

Rene Goedkoop is Acting Officer of Medigene AG
Phone49 89 2000 330
Webhttps://www.medigene.com

Medigene Management Efficiency

The company has return on total asset (ROA) of 0.0887 % which means that it generated a profit of $0.0887 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1768 %, meaning that it generated $0.1768 on every $100 dollars invested by stockholders. Medigene's management efficiency ratios could be used to measure how well Medigene manages its routine affairs as well as how well it operates its assets and liabilities.
Medigene AG has accumulated 3.73 M in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. Medigene AG has a current ratio of 5.92, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Medigene until it has trouble settling it off, either with new capital or with free cash flow. So, Medigene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medigene AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medigene to invest in growth at high rates of return. When we think about Medigene's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 10 records

INSIDER Age

Stephen JDGeron
74
PharmD YoungProcessa Pharmaceuticals
71
Ido MerfeldQrons Inc
58
Linda JDNorthwest Biotherapeutics
67
David InnesNorthwest Biotherapeutics
N/A
Robert FloydProcessa Pharmaceuticals
68
Jonah MeerQrons Inc
68
Jean DavisNorthwest Biotherapeutics
51
, MBANorthwest Biotherapeutics
64
PharmD BigoraProcessa Pharmaceuticals
64
Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company was founded in 1994 and is headquartered in Munich, Germany. Medigene operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 61 people. Medigene AG [MDGEF] is a Pink Sheet which is traded between brokers as part of OTC trading.

Management Performance

Medigene AG Leadership Team

Elected by the shareholders, the Medigene's board of directors comprises two types of representatives: Medigene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigene. The board's role is to monitor Medigene's management team and ensure that shareholders' interests are well served. Medigene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigene's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dolores Schendel, Member of the Executive Board, Chief Scientific officer
Birger Kohlert, Chief Officer
ErnstLudwig Winnacker, Member of the Supervisory Board
MBBS BS, CEO Board
Rene Goedkoop, Acting Officer

Medigene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Medigene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Other Consideration for investing in Medigene Pink Sheet

If you are still planning to invest in Medigene AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigene's history and understand the potential risks before investing.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments